Please assess the completion status of the following clinical trial:

Trial Title: Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a diagnosis of Epilepsy with Simple Partial Seizures (motor component) and or Complex Partial Seizures (with or without secondary generalization)~* Must be experiencing 2 to 40 seizures per 28-day period~* Stable dose of 1 or 2 marketed antiepileptic drugs~* Second Antiepileptic Drug (AED) must be less than or equal to 50 % of the minimum recommended maintenance dose per USA product label at screening~Exclusion Criteria:~* Subject has a history of primary generalized or unclassified seizures~* Seizure disorder primarily characterized by isolated auras~* History of status epilepticus~* Seizures that are uncountable due to clustering~* Has greater than 5 seizures/day~* Subjects taking Benzodiazepines, Phenobarbital or Primidone~* Subject has Vagus Nerve Stimulation (VNS)~* Significant medical or psychiatric condition~* History of alcohol or drug abuse~* History of Ethosuximide use, Felbamate use after 1994 or Vigabatrin use after 1997

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide 400 mg/day (Type: EXPERIMENTAL): Lacosamide 400 mg/day
- Lacosamide 300 mg/day (Type: ACTIVE_COMPARATOR): Lacosamide 300 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).